This article is a US Government work and, as such, is in the public domain in the United States of America.
Basic Science Review
Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck†
Article first published online: 2 APR 2007
Copyright © 2007 Wiley Periodicals, Inc.
Head & Neck
Volume 29, Issue 10, pages 959–971, October 2007
How to Cite
Allen, C. T., Ricker, J. L., Chen, Z., Van Waes, C. (2007), Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck, 29: 959–971. doi: 10.1002/hed.20615
- Issue published online: 11 SEP 2007
- Article first published online: 2 APR 2007
- Manuscript Accepted: 6 DEC 2006
- NIH-Pfizer Clinical Research Training Program Award
- NIDCD Project. Grant Number: DC-00016
- nuclear factor-κB;
- signal transduction;
- head and neck squamous cell carcinoma;
Nuclear factor-κB (NF-κB), a transcription factor known to modulate expression of factors involved in inflammation, immunity, proliferation, and apoptosis, is constitutively activated and plays a role in pathogenesis and therapeutic resistance in head and neck squamous cell carcinoma (HNSCC). Understanding the molecular alterations leading to aberrant NF-κB activation in HNSCC may direct investigators to novel therapeutic targets.
Results of laboratory and clinical studies are reviewed.
The structure, function, and activation of NF-κB, products of NF-κB target genes and their role in HNSCC oncogenesis, and current NF-κB modulating interventions are described.
Aberrant NF-κB activation contributes to the expression of oncogenes and the malignant phenotype observed in HNSCC. NF-κB, along with providing a link between cancer and inflammation, may serve as an appropriate therapeutic target to inhibit tumor growth and sensitize cancer cells to established cytotoxic anticancer therapies. © 2007 Wiley Periodicals, Inc. Head Neck, 2007